Appendix 318 van Gils MJ, van Willigen HDG, Wynberg E, Han AX, van der Straten K, Burger JA, Poniman M, Oomen M, Tejjani K, Bouhuijs JH, Verveen A, Lebbink R, Dijkstra M, Appelman B, Lavell AHA, Caniels TG, Bontjer I, van Vught LA, Vlaar APJ, Sikkens JJ, Bomers MK, Russell CA, Kootstra NA, Sanders RW, Prins M, de Bree GJ, de Jong MD; RECoVERED Study Group. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Rep Med. 2021 Dec 14;3(1):100486. doi: 10.1016/j.xcrm.2021.100486. PMID: 35103254; PMCID: PMC8668345. van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, Burger JA, Oomen M, Bouhuijs JH, van Vught LA, Slim MA, Schinkel M, Wynberg E, van Willigen HDG, Grobben M, Tejjani K, van Rijswijk J, Snitselaar JL, Caniels TG; Amsterdam UMC COVID-19 S3/HCW study group; Vlaar APJ, Prins M, de Jong MD, de Bree GJ, Sikkens JJ, Bomers MK, Sanders RW. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med. 2022 May 17;19(5):e1003991. doi: 10.1371/journal.pmed.1003991. PMID: 35580156; PMCID: PMC9113667. van der Straten K, Guerra D, van Gils MJ, Bontjer I, Caniels TG, van Willigen HDG, Wynberg E, Poniman M, Burger JA, Bouhuijs JH, van Rijswijk J, Olijhoek W, Liesdek MH, Lavell AHA, Appelman B, Sikkens JJ, Bomers MK, Han AX, Nichols BE, Prins M, Vennema H, Reusken C, de Jong MD, de Bree GJ, Russell CA, Eggink D, Sanders RW. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity. 2022 Sep 13;55(9):1725-1731.e4. doi: 10.1016/j.immuni.2022.07.018. Epub 2022 Aug 5. PMID: 35973428; PMCID: PMC9353602. Verveen A, Wynberg E, van Willigen HDG, Davidovich U, Lok A, Moll van Charante EP, de Jong MD, de Bree G, Prins M, Knoop H, Nieuwkerk PT; RECoVERED Study Group. Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study. BMC Med. 2022 Nov 2;20(1):422. doi: 10.1186/s12916-022-02615-7. PMID: 36324167; PMCID: PMC9629769. Wynberg E, de Bree GJ, Leenstra T, Verveen A, van Willigen HDG, de Jong MD, Prins M, Boyd A, the RECoVERED Study Group. Selection of long COVID symptoms influences prevalence estimates in a prospective cohort. medRxiv 2022.11.09.22282120; doi. org/10.1101/2022.11.09.22282120
RkJQdWJsaXNoZXIy MTk4NDMw